![Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates | Nature Communications Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-29219-2/MediaObjects/41467_2022_29219_Fig1_HTML.png)
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates | Nature Communications
![COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/ec1bbbc9-0d70-47da-a8ee-b885b4d05720/gr1.jpg)
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases
![COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7104e2_IncidenceDeathRatesOmicron_IMAGE_21Jan22_1200x675.jpg?_=63959)
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR
![Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070483/F4.medium.jpg)
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
Mixed vaccine schedules offer strong booster responses after two doses of CoronaVac vaccine CORONAVIRUSVACCINES — Target Discovery Institute
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/a32eadc3-c40a-4350-b4c1-6d9cee96f31a/gr1.jpg)
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Infectious Diseases
![Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England | Nature Medicine Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01699-1/MediaObjects/41591_2022_1699_Fig1_HTML.png)
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England | Nature Medicine
![Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health](https://www.thelancet.com/cms/asset/317ba83b-0864-4f92-bfd5-473f45a92e43/gr1.gif)
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675.jpg)
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
![Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine | Nature Communications Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-29578-w/MediaObjects/41467_2022_29578_Fig1_HTML.png)
Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine | Nature Communications
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig2_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![How much better are updated COVID boosters? Pfizer announces first results in human clinical trial - CBS News How much better are updated COVID boosters? Pfizer announces first results in human clinical trial - CBS News](https://assets3.cbsnewsstatic.com/hub/i/r/2022/10/13/65087a3a-8a14-40d8-8ffb-6cf328c9a635/thumbnail/1280x720/eb97f507b7f09fc5aec1063ecfba7b18/cbsn-fusion-fda-authorizes-updated-covid-boosters-for-kids-ages-five-to-11-thumbnail-1373830-640x360.jpg)